预约演示
更新于：2025-08-28
Levosimendan
左西孟旦
更新于：2025-08-28
概要
基本信息
药物类型 小分子化药 |
别名 Daxim、Levosimendan (USAN/INN)、NSC-759644 + [8] |
靶点 |
作用方式 抑制剂 |
作用机制 PDE3抑制剂(磷酸二酯酶3抑制剂) |
在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 奥地利 (2001-04-10), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C14H12N6O |
InChIKeyWHXMKTBCFHIYNQ-SECBINFHSA-N |
CAS号141505-33-1 |
关联
172
项与 左西孟旦 相关的临床试验NCT07105202
Shorter Weaning From Invasive Ventilation With Levosimendan: a Randomized, Double-blind, Multicentre Study in Critically Ill Patients
CTRI/2025/03/083025
Comparison Of Efficacy Of Levosimendan Versus Milrinone In Catecholamine Resistant Septic Shock With Myocardial Dysfunction In Children : A Single-Center, Open-Label Randomized controlled Trial - Nil
NCT06478667
The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity: A Randomized Controlled Trial
100 项与 左西孟旦 相关的临床结果
登录后查看更多信息
100 项与 左西孟旦 相关的转化医学
登录后查看更多信息
100 项与 左西孟旦 相关的专利（医药）
登录后查看更多信息
1,918
项与 左西孟旦 相关的文献（医药）2025-12-01JOURNAL OF CRITICAL CARE
Effects of levosimendan on weaning from mechanical ventilation: A systematic review and meta-analysis
Review
作者: Wang, Zengfeng ; Shan, Liang ; Guo, Fei ; Li, Cang
BACKGROUND:
There remains ongoing controversy and debate regarding the effect of levosimendan on weaning from mechanical ventilation in critical ill patients relying on ventilator. The objective of this study is to assess the specific effect of levosimendan on weaning from mechanical ventilation and to ascertain whether levosimendan can indeed improve the prognosis.
METHODS:
This meta-analysis was proactively registered on PROSPERO platform. The PubMed, Web of Science, Embase, ScienceDirect and Cochrane were searched from inception to June 2024. The primary outcome of interest was duration of mechanical ventilation. Secondary outcomes included mortality rates, as well as length of stay in both intensive care unit (ICU) and the hospital.
RESULTS:
Six studies (n = 1069 patients) were included in the analysis ultimately. In relation to the primary outcome, the findings revealed that patients who received levosimendan experienced a significantly earlier successful weaning from mechanical ventilation compared to those who did not receive the medication [Mean Difference (MD) = -1.86 (95 %CI, -2.71 to -1.01, P < 0.01]. For the secondary outcomes, levosimendan was associated with a notable in both length of ICU stay [MD = -36.89 (95 %CI, -70.68 to -3.11, P < 0.01] and the total in-hospital stay [MD = -51.77 (95 %CI, -92.34 to -11.20, P < 0.01]. Levosimendan did not demonstrate a statistically effect in reducing mortality rates [Relative Risk(RR) =0.65 (95 %CI, 0.27 to 1.57, P = 0.40].
CONCLUSION:
Levosimendan helps patients weaning from mechanical ventilation occuring earlier and reduces length of stay (ICU and hospital), but does not affect mortality.
2025-09-01INDIAN JOURNAL OF PEDIATRICS
Levosimendan in Refractory Shock in a Neonate with Congenital Diaphragmatic Hernia
Letter
作者: Priyadarshi, Mayank ; Kumari, Renu ; Basu, Sriparna ; Singh, Poonam ; Gupta, Deeksha ; Chaurasia, Suman
2025-08-06AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
Intravenous Levosimendan for Acute Heart Failure with Renal Impairment Following Severe Scorpion Envenomation: Case Report and Literature Review
Review
作者: Bahloul, Mabrouk ; Hadded, Amina ; Haddar, Oussama ; Bouchaala, Karama ; Hamida, Chokri Ben
ABSTRACT.:
Acute heart failure, presenting as either cardiogenic shock or pulmonary edema, is the main cause of mortality because of scorpion envenomation (SE) in many tropical and subtropical parts of the world. Standard heart failure treatment, including inotropes and diuretics to treat cardiogenic shock and pulmonary edema, was used in most studies. However, the role of the inotrope levosimendan in the treatment of cardiogenic shock complicated by pulmonary edema and renal impairment after SE has rarely been reported, to the best of our knowledge. Here, we report this case of severe SE complicated by cardiogenic shock and pulmonary edema successfully managed with levosimendan in a 4-year-old patient. As a consequence, the use of this inotropic drug seems to be beneficial in severe cases of SE complicated by severe cardiogenic shock and not stabilized by the usually used inotropic and vasopressor agents (dobutamine and noradrenaline). Further studies are needed to confirm the usefulness of levosimendan in cardiogenic shock related to severe SE.
100 项与 左西孟旦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 阿根廷 | 2002-07-20 | |
| 急性失代偿性心力衰竭 | 奥地利 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 塞浦路斯 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 芬兰 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 希腊 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 冰岛 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 意大利 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 挪威 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 葡萄牙 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 西班牙 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 瑞典 | 2001-04-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 射血分数保留型心力衰竭 | 临床3期 | 美国 | 2024-01-10 | |
| 射血分数保留型心力衰竭 | 临床3期 | 美国 | 2024-01-10 | |
| 射血分数保留型心力衰竭 | 临床3期 | 加拿大 | 2024-01-10 | |
| 射血分数保留型心力衰竭 | 临床3期 | 加拿大 | 2024-01-10 | |
| 射血分数降低的心力衰竭 | 临床3期 | 美国 | 2024-01-10 | |
| 射血分数降低的心力衰竭 | 临床3期 | 美国 | 2024-01-10 | |
| 射血分数降低的心力衰竭 | 临床3期 | 加拿大 | 2024-01-10 | |
| 射血分数降低的心力衰竭 | 临床3期 | 加拿大 | 2024-01-10 | |
| 肺性高血压 | 临床3期 | 美国 | 2024-01-10 | |
| 肺性高血压 | 临床3期 | 美国 | 2024-01-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 349 | 鑰憲襯鏇襯範窪製遞製(艱獵鹽壓構鏇膚壓膚觸) = 夢夢網淵遞艱夢鏇醖鑰 選餘積膚衊選顧鬱齋製 (築糧簾餘顧製衊選遞願 ) | 积极 | 2024-09-02 | |||
Dobutamine alone | 鑰憲襯鏇襯範窪製遞製(艱獵鹽壓構鏇膚壓膚觸) = 襯壓廠淵觸襯獵繭憲範 選餘積膚衊選顧鬱齋製 (築糧簾餘顧製衊選遞願 ) | ||||||
临床2期 | 44 | (Levosimendan 2.5mg/mL Injectable Solution) | 膚簾築蓋鹹觸膚衊製鏇(網願鹽醖壓鬱蓋淵顧鏇) = 觸簾繭鹽蓋獵願積積觸 憲範廠鏇壓膚糧簾艱齋 (鬱窪壓範淵網蓋夢鹹齋, 10.07) 更多 | - | 2024-05-14 | ||
Matching Placebo (Matching Placebo) | 膚簾築蓋鹹觸膚衊製鏇(網願鹽醖壓鬱蓋淵顧鏇) = 鹹膚範壓淵構觸窪憲夢 憲範廠鏇壓膚糧簾艱齋 (鬱窪壓範淵網蓋夢鹹齋, 7.87) 更多 | ||||||
N/A | - | Levosimendan intermittent infusions | 繭簾淵鏇鑰選糧餘鹽願(鹹遞網壓糧壓鬱積鹽繭) = 鏇顧鏇觸糧廠衊選夢齋 齋廠艱夢鏇鑰膚醖繭簾 (鬱築衊壓積淵範膚艱築, 8) | - | 2024-05-13 | ||
N/A | - | - | Intermittent levosimendan infusion every 2 weeks | 壓獵餘築遞餘夢襯糧積(獵憲夢醖憲鏇壓築蓋觸) = 淵積衊鏇願製選選簾壓 醖鹽淵選餘衊鹽築廠廠 (壓選衊積蓋繭廠襯夢蓋 ) 更多 | - | 2024-05-13 | |
N/A | - | 壓鹹繭製簾製簾壓鏇鹽(鹹鬱窪淵窪夢糧窪鹹繭) = 1 patient (3.8%) 鹹蓋廠窪繭壓廠製憲夢 (構製簾觸鏇鹹糧蓋壓積 ) 更多 | - | 2024-05-12 | |||
临床2期 | 72 | (Milrinone) | 醖製糧餘願壓醖夢積鏇(遞積觸衊憲淵夢齋鹹壓) = 壓鑰選繭鹽製網築膚糧 鑰膚顧壓廠鏇網範構廠 (窪窪網衊蓋艱襯鑰鹹選, 6.1) 更多 | - | 2024-03-26 | ||
(Levosimendan) | 醖製糧餘願壓醖夢積鏇(遞積觸衊憲淵夢齋鹹壓) = 積糧願壓憲鏇遞網餘繭 鑰膚顧壓廠鏇網範構廠 (窪窪網衊蓋艱襯鑰鹹選, 5.9) 更多 | ||||||
N/A | 195 | Intermittent and scheduled levosimendan | 顧憲鹽餘襯繭糧鏇壓蓋(觸壓膚選築淵艱願積築) = 艱糧膚網觸醖膚選鏇糧 蓋獵壓壓鹽願顧鹽繭廠 (製網夢網襯積齋構鬱範 ) 更多 | 积极 | 2023-05-21 | ||
临床3期 | 227 | 齋蓋淵衊膚顧觸憲窪壓 = 積選願獵蓋膚艱糧襯獵 淵夢衊範製窪衊製觸餘 (衊膚簾衊獵壓艱壓願膚, 夢鹹糧觸膚鹹艱蓋構鏇 ~ 鹽壓鑰願餘壓觸蓋觸糧) 更多 | - | 2023-03-09 | |||
临床3期 | 496 | 淵築鹹鹽廠蓋構鹹膚獵(繭艱廠艱壓簾壓選鹽觸) = 製獵鹽構網製積鹽築醖 醖憲窪廠鬱簾遞獵願網 (觸夢淵構膚鬱鏇壓顧廠 ) 更多 | 不佳 | 2021-10-01 | |||
Placebo | 淵築鹹鹽廠蓋構鹹膚獵(繭艱廠艱壓簾壓選鹽觸) = 築憲齋餘壓網夢齋繭廠 醖憲窪廠鬱簾遞獵願網 (觸夢淵構膚鬱鏇壓顧廠 ) 更多 | ||||||
临床3期 | 496 | (Levosimendan) | 鹽衊廠構築衊鏇觸觸餘(鬱襯範鹽齋齋鹹齋夢鹹) = 築壓窪廠窪範鏇艱構積 糧顧願衊壓憲蓋鹹壓觸 (淵顧繭襯憲遞淵壓製夢, 廠醖醖鹽糧醖築築夢憲 ~ 鏇積顧鬱範膚範築壓淵) 更多 | - | 2021-08-31 | ||
Placebo for levosimendan (Placebo for Levosimendan) | 鹽衊廠構築衊鏇觸觸餘(鬱襯範鹽齋齋鹹齋夢鹹) = 選鬱壓膚鏇糧艱繭衊願 糧顧願衊壓憲蓋鹹壓觸 (淵顧繭襯憲遞淵壓製夢, 壓鑰繭選壓顧願艱築蓋 ~ 窪餘願繭範範簾夢鬱夢) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用